BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $15.50.

Several research firms have commented on BCRX. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Needham & Company LLC upped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays upped their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th.

BioCryst Pharmaceuticals Stock Up 2.6 %

NASDAQ BCRX opened at $9.05 on Monday. The company has a market cap of $1.87 billion, a PE ratio of -14.84 and a beta of 1.75. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.11. The firm’s 50-day simple moving average is $7.86 and its two-hundred day simple moving average is $7.77.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Venturi Wealth Management LLC purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $46,000. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $48,000. Mirae Asset Global Investments Co. Ltd. raised its stake in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. KBC Group NV raised its stake in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $80,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.